ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease

Published: 11/01/2019
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
Source: WWW.BUSINESSWIRE.COM

TEL AVIV, Israel--(BUSINESS WIRE)--ChemomAb, a clinical-stage biopharmaceutical company focused on the development of novel therapies for fibrotic-inflammatory diseases, announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease (NAFLD) patients. The company’s lead investigational drug candidate, CM-101, is targeting the

Read more
Related news
Comment
FACEBOOK